T1G3R-1 Trial: Detectability and Prognostic Value of ctDNA in T1 G3 Bladder Cancer
Recruiting now
Conditions studied: Bladder Cancer
In brief
T1G3 bladder cancer is a heterogeneous disease with a high risk of disease persistence after the first TUR-B, understaging, disease progression, bladder removal, and mortality. Current risk stratification is insufficient and needs improvement. Ct-DNA could identify patients with disease persistence, progression and could monitor and tailor therapy. It might improve patient risk stratification, avoiding under- and overtreatment, reducing morbidity and mortality. Primary objective is to investigate the detectability of ct-DNA in T1G3 urothelial bladder cancer patients and build a biobank through collection of different sample types (urine, plasma) in T1G3 bladder cancer patients which allows future retrospective testing.
Key facts
- Study ID
- NCT07581496
- Run by
- University Hospital, Basel, Switzerland
- People needed
- 35
- Starts
- 2025-06-18
- Expected to finish
- 2030-06-01
- Last updated by the study team
- 2026-05-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- patients > 18 years of age, able to give informed consent as documented by signature,
- patients with a cystoscopically proven bladder cancer, suspicious for T1 stage, who will undergo TUR-B
You may not qualify if…
- Patients with metastases or concomitant upper tract tumor at diagnosis will
- Patients with non T1 G3 cancers
- Patients with upstaging, either at re-TUR-B or after immediate radical cystectomy
- Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc.
- Vulnerable persons (e.g. < 18y of age, unable to consent to the study)
Where it is running
- Universitätsspital Basel — Basel, Switzerland (enrolling)
- Luzerner Kantonsspital — Lucerne, Switzerland (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.